Daiwa Securities Group
MLYS icon

Daiwa Securities Group’s Mineralys Therapeutics MLYS Stock Holding History

Daiwa Securities Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-235
Closed -$9K – 1339
2025
Q4 		$9K Buy
235
+36
+18% +$1.44K ﹤0.01% 1193
2025
Q3 		$8K Sell
199
-35
-15% -$757 ﹤0.01% 1171
2025
Q2 		$3K Buy
234
+82
+54% +$1.19K ﹤0.01% 1193
2025
Q1 		$2K Hold
152
– – ﹤0.01% 1187
2024
Q4 		$2K Hold
152
– – ﹤0.01% 1220
2024
Q3 		$2K Hold
152
– – ﹤0.01% 1222
2024
Q2 		$2K Hold
152
– – ﹤0.01% 1254
2024
Q1 		$2K Buy
+152
New +$1.88K ﹤0.01% 1272

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Daiwa Securities Group's MLYS Position: Q1 2026 in Review

Daiwa Securities Group sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 235 shares — an estimated $9K sold.

Daiwa Securities Group first reported a position in MLYS in Q1 2024 and held it in 8 quarters. The position peaked at $9K in Q4 2025. 215 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Daiwa Securities Group reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 235 Mineralys Therapeutics shares in Q1 2026, an estimated $9K.
  • Daiwa Securities Group first reported a position in Mineralys Therapeutics in Q1 2024 and held it in 8 quarters.
  • Daiwa Securities Group's Mineralys Therapeutics position peaked at $9K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.